FDA extends PDUFA for Pegunigalsidase alfa (PRX–102) in Fabry disease

Pegunigalsidase alfa (PRX–102) update : Protalix BioTherapeutics said that the US Food and Drug Administration (FDA) has extended the prescription drug user fee act (PDUFA) ... Read More